Evoke製藥 EVOK 深 滬
等待開盤 08-14 09:30:00 美东时间
5.07
+0.080
+1.60%
華盛通- 最 高5.08
- 今 開4.62
- 成交量 2.11万股
- 最 低 4.61
- 昨 收 4.99
- 總市值 756.90万
- 52周最高 12.3199
- 市盈率 靜 --
- 換手率 1.41%
- 52周最低 1.94
- 委 比 80.18%
- 總股本 149.29万
- 歷史最高 2052.00
- 量 比 0.22
- 振 幅 9.42%
- 歷史最低 1.94
- 每 手 1
- 風險率 1.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Evoke Pharma Secures New U.S. Patent For GIMOTI Nasal Spray Targeting Moderate To Severe Gastroparesis
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the
08-06 18:37
【天风医药杨松团队|公司深度研究】科伦博泰生物：TROP2 ADC具备BIC潜力，全球多中心三期临床积极拓展
（来源：一棵大松树） 携手默沙东深耕TROP2ADC全球布局，具有BIC潜力 芦康沙妥珠单抗（SKB264）是公司自主研发的一款靶向...
08-06 15:27
Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038
Evoke Pharma has received U.S. Patent No. 12,377,064, extending GIMOTI®'s exclusivity to November 2038, nearly two additional years beyond the original 2036 projection. The patent covers the use of intranasal metoclopramide for treating moderate to severe gastroparesis symptoms, strengthening GIMOTI's intellectual property position. The company plans to list the patent in the FDA's Orange Book, enhancing its market protection. CEO Matt D’Onofrio ...
08-06 10:30
Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On?
Shares of Evoke Pharma are trading sharply higher Wednesday morning. The specialty pharma company received a U.S. Patent Office Notice of Allowance for a new patent on its lead product, GIMOTI.
07-09 23:15
Evoke Pharma Receives Notice Of Allowance From USPTO For U.S. Patent Application Covering Use Of GIMOTI In Patients With Moderate To Severe Symptoms Of Gastroparesis
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that
07-09 20:18
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036
Evoke Pharma has received a Notice of Allowance from the USPTO for a patent covering the use of GIMOTI® in patients with moderate to severe gastroparesis. The patent will expire in December 2036 and extend market exclusivity for GIMOTI. CEO Matt D’Onofrio highlighted the value of this patent in protecting the therapy’s use and application. GIMOTI is the only FDA-approved non-oral metoclopramide spray for diabetic gastroparesis, addressing challen...
07-09 12:16
Evoke plc Director Joins Grafton Group Board
An update from 888 Holdings ( ($GB:EVOK) ) is now available. Evoke plc has anno...
06-18 15:32
吉利德走出水逆？
原标题：吉利德走出水逆？ 2024年，吉利德堪称水逆王 者。 重金收购的Trodelvy，在非小细胞肺癌和尿路上皮癌的三期临床试验中接连失利，并撤回尿路上皮癌...
05-30 09:58
Evoke PLC Announces Executive Bonus Share Purchase
888 Holdings ( ($GB:EVOK) ) has shared an announcement. Evoke PLC has announced...
05-28 00:42
Evoke Pharma Holds Annual Meeting via Webcast
Evoke Pharma ( ($EVOK) ) has shared an announcement. Evoke Pharma held its Annu...
05-23 05:25
